Duncan Chen (陳嘉宏)

duncan19760605@gmail.com

WORK EXPERIENCE

2008~2011	聚和國際/聚天生醫	*Project Manager/* New Drug Development
2011~	Original Biomedical Co., Ltd (原創生醫)	*Chairman/CTO*
2017~	Genius Holdings Co., Ltd. (薩摩亞傑尼斯)	*CTO/Co Founder*
2018~	Genius Holdings Co., Ltd. (薩摩亞傑尼斯)	*CEO/Chairman*

EDUCATION

1999~2001	Tzu Chi University	*Master of Science in Pharmacology and Toxicology*
2014~	National Taiwan University	*International Business, EMBA Student*
2012~2014	National Taiwan University	*College of Medicine Graduate Institute of Toxicology, PhD Student*

CERTIFICATE

- **Senior Securities Specialist**
- **GCP**

Duncan has more than 17 years' experience in medical industries, such as hospital, biotechnology, pharmaceuticals, and medical devices. He is well-experienced in drug development and initiated a drug delivery technology company from 80,000 USD to 70 million USD market values within 3 years (2011~2014, Original BioMedicals http://www.i-obm.com). Their major drug development project is undergoing Phase I clinical trial at US, and licensing the future development right at China, South Korea, and Japan in cancer treatment combination therapeutically indications. He has 2 innovation patents in drug delivery, and 2 innovation patents in ultrasound technology applied with medical device spirometer. All inventions are submitted to global IPs in worldwide.

He also takes responsibility to help Genius Holding team to make the ultrasound technology to become a realistic product ezOxygen and continue the creative medical devices development process.

PATENT/INNOVATION

Ultrasound Application Patents: (Global IP, just list US patent application)

- https://patents.google.com/patent/US20230027916A1
- https://patents.google.com/patent/US20230310936A1

Medical Device Patents: (Global IP, just list US patent application)

- https://patents.google.com/patent/US10863923B2
- https://patents.google.com/patent/US20170042503A1
- https://patents.google.com/patent/US20220354736A1

Pharmaceutical Patens: (Global IP, just list US patent application, or currently only public areas)

- https://patents.google.com/patent/US9597406B2
- https://patents.google.com/patent/US9211341B2
- https://patents.google.com/patent/US9226967B2
- https://patents.google.com/patent/US9220786B2
- https://patents.google.com/patent/US9700623B2
- https://patents.google.com/patent/US8785569B2
- https://patents.google.com/patent/TWI818601B
- https://patents.google.com/patent/TW202310881A

RESEARCH

- The Antimicrobial Effects of Colistin Encapsulated in Chelating Complex Micelles for the Treatment of Multi-Drug-Resistant Gram-Negative Bacteria: A Pharmacokinetic Study. Antibiotics (Basel) . 2023 Apr 30;12(5):836. (https://pubmed.ncbi.nlm.nih.gov/37237739/)
- Chelating Complex Micelles for Delivering Cytoprotectant Amifostine and its Application in Radiation Protection. J Pharmacovigil 2018, 6:3 (https://www.semanticscholar.org/paper/Chelating-Complex-Micelles-for-Delivering-and-its-Wang-Cheng/ef3cf22fee50148c716e975cc6c6917893d23dee)
- CCM-AMI, a Polyethylene Glycol Micelle with Amifostine, as an Acute Radiation Syndrome Protectant in C57BL/6 Mice. Health Phys . 2015 Sep;109(3):242-8. (https://pubmed.ncbi.nlm.nih.gov/26222219/)
- A Phase I Study to Evaluate the Safety and Pharmacokinetics of RadProtect® in Healthy Volunteers (https://clinicaltrials.gov/study/NCT02587442)
- Hydrogen peroxide increases the activity of rat sympathetic preganglionic neurons in vivo and in vitro. Neuroscience. 2003;121(3):641-7. (https://www.ncbi.nlm.nih.gov/pubmed/14568024)
- CCM-AMI, a Polyethylene Glycol Micelle with Amifostine, as an Acute Radiation Syndrome Protectant in C57BL/6 Mice. Health Phys. 2015;109(3):242-8 (https://www.ncbi.nlm.nih.gov/pubmed/26222219)
- 農業生技代表性個案 Dow Chemical 分析，台灣經濟研究院生物科技產業研究中心，2007，陳嘉宏
- 台灣保健食品類食品產業概況分析，台灣經濟研究院生物科技產業研究中心，2006，陳嘉宏
- 台灣沖調養生類食品產業概況分析，台灣經濟研究院生物科技產業研究中心，2006，陳嘉宏
- 台灣醫療器材產業分析，台灣經濟研究院生物科技產業研究中心，2006，陳嘉宏
- 生技製藥產業之分工與合作模式：以瑞士 Roche 藥廠為例，台灣經濟研究院生物科技產業研究中心，2006，陳嘉宏
- 台灣西藥製藥產業分析，，台灣經濟研究院生物科技產業研究中心，2006，陳嘉宏
- 農業生技大廠 Monsanto 個案分析，台灣經濟研究院生物科技產業研究中心，2006，陳嘉宏

- 農業生技大廠 Syngenta 個案分析，台灣經濟研究院生物科技產業研究中心，2006，陳嘉宏
- 台灣健康食品產業及法規概述，台灣經濟研究院生物科技產業研究中心，2006，陳嘉宏
- 國外健康食品產業分析，台灣經濟研究院生物科技產業研究中心，2005，陳嘉宏
- A Pilot Study in Combination Docetaxel and Oxaliplatin with Weekly Chemotherapy Regimen in Non-Small Cell Lung Cancer 以每週一次療程併用歐洲紫杉醇及第三代鉑金類抗癌藥品在非小細胞肺癌患者的前驅臨床試驗，2005，陳嘉宏